DCR-AUD
Alcohol Use Disorder
Phase 1Status Unknown Post-Acquisition
Key Facts
Indication
Alcohol Use Disorder
Phase
Phase 1
Status
Status Unknown Post-Acquisition
Company
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals established itself as a leader in next-generation RNAi therapeutics through its proprietary, liver-targeted GalXC™ and GalXC-Plus™ technology platforms. The company advanced a promising pipeline, most notably nedosiran for primary hyperoxaluria, and forged significant partnerships with industry leaders like Novo Nordisk, Roche, and Eli Lilly. Its successful trajectory culminated in a strategic acquisition by Novo Nordisk in December 2021, integrating Dicerna's platform to expand the acquirer's capabilities in genetic medicine for cardiometabolic and rare diseases.
View full company profileTherapeutic Areas
Other Alcohol Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Neurology Research | Renovaro BioSciences | Research |
| Alcohol Use Disorder Program | Lunai Bioworks | Discovery |